Discovery of the First Highly Potent, Selective, Irreversible Small-Molecule Factor XIIa Inhibitor for Treating Sepsis
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c01243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Lei Geng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, China. Hauptthemen laut MEDLINE: Sepsis, Factor XIIa, Drug Discovery, Anticoagulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Anhui Province.
Themen: Sepsis
Abstract (Originalsprache)
Factor XIIa (FXIIa), a key serine protease at the intersection of coagulation and inflammation, has emerged as an attractive therapeutic target in recent years. To date, 1,2,4-triazol-5-amine-based covalent inhibitors constitute the most extensively investigated class of FXIIa inhibitors. However, the majority of these compounds have not progressed further in development, largely due to limitations such as insufficient plasma stability and transient, reversible target engagement. To address these shortcomings, we conducted structure-guided optimization and designed a series of derivatives featuring a distinct tricyclic scaffold. Among these, F38 exhibited a mechanistic shift toward irreversible binding, resulting in markedly improved FXIIa inhibition (IC50 = 2 nM) along with enhanced anticoagulant activity (EC1.5X = 11 μM) and anti-inflammatory effects. Notably, F38 demonstrated significant therapeutic benefit in a mouse model of LPS-induced sepsis, substantially reducing mortality and highlighting its promise as a candidate for further preclinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, China.
- The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
- Clinical Laboratory Department, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei 230001, China.
- Department of Pharmaceutical Sciences and Engineering, Anhui Provincial International Science and Technology Cooperation Base for Major Metabolic Diseases and Nutritional Interventions, School of Food and Biological Eng…
ORCID-Profile: Yang Xu, Xiaoxiao Yang, Zhouling Xie
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
Zitieren
APA
Geng, L., Dong, L., Chen, F., Wang, S., Cheng, D., Zheng, N., Chen, Z., Xu, Y., Yang, X., Chen, Y., & Xie, Z. (2026). Discovery of the First Highly Potent, Selective, Irreversible Small-Molecule Factor XIIa Inhibitor for Treating Sepsis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01243
Vancouver
Geng L, Dong L, Chen F, Wang S, Cheng D, Zheng N, et al. Discovery of the First Highly Potent, Selective, Irreversible Small-Molecule Factor XIIa Inhibitor for Treating Sepsis. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01243
BibTeX
@article{Geng2026,
author = {Geng, Lei and Dong, Liang and Chen, Fangrong and Wang, Shouwei and Cheng, Dan and Zheng, Nan and Chen, Zhengxu and Xu, Yang and Yang, Xiaoxiao and Chen, Yuanli and Xie, Zhouling},
title = {Discovery of the First Highly Potent, Selective, Irreversible Small-Molecule Factor XIIa Inhibitor for Treating Sepsis},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c01243}
}
EUVIMED